GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xbrane Biopharma AB (STU:7XB) » Definitions » Price-to-Funds-From-Operations

Xbrane Biopharma AB (STU:7XB) Price-to-Funds-From-Operations : (As of May. 26, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Xbrane Biopharma AB Price-to-Funds-From-Operations?

Price-to-Funds-From-Operations only applies to REITs.


Xbrane Biopharma AB (STU:7XB) Business Description

Industry
Traded in Other Exchanges
Address
Retzius vag 8, Solna, SWE, 171 65
Xbrane Biopharma AB is a biotechnology company that develops biosimilars. The company has a patented protein production platform with up to 12 times greater productivity than standard systems for the production of proteins in E.coli host cells. Xbrane's leading product candidate is Ximluci, a ranibizumab biosimilar (original drug Lucentis) used in the treatment of various eye diseases, mainly the wet form of age-related macular degeneration. The company's geographical segments include the Middle East, Asia, Europe, and the United States.